Company Description
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease.
It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.
Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 1998 |
| IPO Date | Feb 3, 2010 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 253 |
| CEO | Thomas McCourt |
Contact Details
Address: 100 Summer Street, Suite 2300 Boston, Massachusetts 02110 United States | |
| Phone | 617 621 7722 |
| Website | ironwoodpharma.com |
Stock Details
| Ticker Symbol | IRWD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001446847 |
| CUSIP Number | 46333X108 |
| ISIN Number | US46333X1081 |
| Employer ID | 04-3404176 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas A. McCourt | Chief Executive Officer and Director |
| John Minardo | Senior Vice President, Chief Legal Officer and Secretary |
| Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Senior Vice President and Head of Research and Drug Development |
| Greg Martini | Senior Vice President, Chief Financial Officer and Investor Relations |
| Ronald Silver | Senior Vice President, Corporate Controller and Principal Accounting Officer |
| Dr. Rosario Lobrutto M.B.A., M.S., Ph.D. | Vice President and Global Head of Technical Operations |
| Mike Nanfito | Vice President of Sales and Sales Excellence |
| Tammi Gaskins | Senior Vice President and Chief Commercial Officer. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | SCHEDULE 13G | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| May 2, 2025 | SCHEDULE 13G/A | Filing |
| May 2, 2025 | SCHEDULE 13G | Filing |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | 8-K | Current Report |